Novo Nordisk Raises Full-Year Guidance as Wegovy Pill Sales Beat Estimates by 17%

Novo Nordisk has raised its full-year revenue and operating profit guidance for 2026, driven by surging third-quarter demand for the oral version of its blockbuster weight-loss drug, Wegovy. The Danish pharmaceutical company reported that sales of the daily pill exceeded Wall Street estimates by 17 percent.[4][6]

The upward revision marks the third time this year that Novo Nordisk has adjusted its financial outlook. Management now expects total sales growth of 24 to 28 percent for the year, up from the previous range of 22 to 27 percent.[3][5]

Operating profit growth is now projected to land between 21 and 25 percent, reflecting improved manufacturing efficiencies and higher margins on the oral formulation. The results sent the company's Copenhagen-listed shares up 4.2 percent in early Wednesday trading.[3]

"The transition from weekly injections to a daily pill has unlocked a completely new demographic of patients," said a senior healthcare analyst at Inderes. "We are seeing unprecedented adherence rates among populations that previously refused injectable treatments."[4]

Oral Formulation Changes Market Dynamics

The introduction of the Wegovy pill represents a critical pivot in the broader market for GLP-1 receptor agonists. Until recently, the weight-loss sector was entirely dependent on auto-injector pens, which are complex to manufacture and prone to persistent supply chain bottlenecks.[1][2]

By shifting a significant portion of its patient base to a tablet, Novo Nordisk has effectively bypassed the global shortage of sterile fill-finish capacity. The oral medication utilizes standard solid-dose manufacturing lines, which are cheaper to operate and vastly easier to scale.[5][6]

Third-quarter data indicates that 42 percent of new Wegovy prescriptions in the United States were written for the pill rather than the pen. That figure represents a sharp increase from just 18 percent during the first quarter of 2026.[6]

European markets are showing a similar trajectory following the pill's regulatory approval in the European Union late last year. In Germany and the United Kingdom, early adoption rates for the oral formulation have outpaced initial projections by more than 30 percent.[3][5]

Defending Territory Against Eli Lilly

The strong performance of the Wegovy pill provides Novo Nordisk with a crucial strategic advantage in its ongoing battle with American rival Eli Lilly. Lilly's competing weight-loss drug, Zepbound, remains available only as a weekly injection.[5]

While Zepbound has demonstrated slightly higher average weight loss in clinical trials, the convenience of a daily tablet is proving to be a powerful differentiator. Physicians report that needle anxiety remains a primary reason patients discontinue GLP-1 therapies within the first three months.[1][5]

"Novo Nordisk has essentially traded a marginal efficacy advantage for a massive convenience advantage," noted a market report from Euronext. "In a consumer-driven healthcare market, the easiest treatment protocol usually wins the largest share of the patient population."[5]

To maintain this momentum, Novo Nordisk has committed an additional $4.2 billion to expand its active pharmaceutical ingredient manufacturing facilities in Denmark and the United States. The investment aims to double the company's tablet production capacity by the end of 2027.[2][3]

Expanding Insurance Coverage

The financial success of the third quarter was also bolstered by expanding insurance coverage for weight-loss medications. Over the past six months, three major US health insurers have added the Wegovy pill to their preferred formularies.[6]

Coverage expansion has been heavily influenced by recent clinical trial data demonstrating that Wegovy reduces the risk of major adverse cardiovascular events by 20 percent. Insurers are increasingly viewing the medication as a preventative cardiovascular treatment rather than a purely cosmetic weight-loss aid.[1][2]

The shift in classification has allowed Novo Nordisk to secure more favorable pricing agreements with pharmacy benefit managers. The average net price realized per prescription increased by 4.5 percent in the third quarter compared to the same period last year.[3][6]

Despite the higher net price, out-of-pocket costs for insured patients have actually decreased. The company reported that 78 percent of commercially insured US patients now pay less than $50 per month for their Wegovy prescriptions.[6]

Global Supply Chain Resilience

The transition to oral medications has fundamentally altered Novo Nordisk's supply chain risk profile. The company's reliance on specialized glass syringes and complex assembly machines has decreased significantly over the past twelve months.[1][5]

This resilience was tested during recent disruptions in the global plastics market, which delayed the production of auto-injector components for several competing pharmaceutical firms. Novo Nordisk's tablet production lines continued to operate at full capacity throughout the shortage.[5]

The company's $16.5 billion acquisition of manufacturing giant Catalent, finalized earlier this year, is now fully integrated into its production network. Three former Catalent facilities have been retrofitted exclusively for GLP-1 tablet manufacturing.[2][3]

"The Catalent integration was executed flawlessly, and we are already seeing the promised synergies in our third-quarter margins," a Novo Nordisk spokesperson stated during the morning earnings call. "We now control our manufacturing destiny from end to end."[3]

Future Pipeline and Next-Generation Drugs

While the current iteration of the Wegovy pill is driving immediate revenue growth, Novo Nordisk is already preparing its next generation of oral therapies. The company highlighted progress on its experimental drug, amycretin, during the earnings presentation.[1][4]

AI

Amycretin, which targets both GLP-1 and amylin receptors, is currently in Phase 2 clinical trials. Early data suggests the dual-agonist pill could deliver weight loss of up to 13 percent over 12 weeks, potentially matching the efficacy of the most powerful injectable treatments.[4][5]

Research and development spending increased by 19 percent in the third quarter, reaching $1.2 billion. The majority of these funds have been allocated to accelerating clinical trials for oral formulations across the company's broader metabolic disease portfolio.[3]

The company is also exploring combination therapies that pair Wegovy with other cardiovascular medications in a single daily tablet. These combinations are designed to improve patient adherence among older demographics managing multiple chronic conditions.[1][6]

Broader Economic Implications

The sheer scale of Novo Nordisk's success continues to impact the broader Danish economy. The company's market capitalization now exceeds the entire gross domestic product of Denmark, creating unique macroeconomic dynamics for the Nordic nation.[3][5]

The influx of foreign currency from global Wegovy sales has forced the Danish central bank to keep interest rates artificially low to prevent the krone from appreciating too rapidly against the euro. This policy has inadvertently stimulated the domestic housing market.[5]

"Novo Nordisk is no longer just a pharmaceutical company; it is a macroeconomic force," the Euronext report concluded. "Its production decisions and sales forecasts now directly influence national monetary policy and employment rates."[5]

Looking ahead to the fourth quarter, the company expects the sales momentum to accelerate as production capacity continues to expand. Management confirmed that there are currently no supply restrictions on any dose strengths of the Wegovy pill in the US market.[2][6]

The resolution of supply constraints marks a significant milestone for a drug that has been plagued by shortages since its initial launch. Physicians can now prescribe the medication without fear that patients will be unable to fill their prescriptions at local pharmacies.[1][6]

The ultimate test for Novo Nordisk will be maintaining this growth trajectory as Eli Lilly pushes to develop its own oral GLP-1 treatments. For now, the Danish company holds a commanding lead in the most accessible segment of the most lucrative pharmaceutical market in history.[4][5]